MA38688B1 - Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d - Google Patents

Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d

Info

Publication number
MA38688B1
MA38688B1 MA38688A MA38688A MA38688B1 MA 38688 B1 MA38688 B1 MA 38688B1 MA 38688 A MA38688 A MA 38688A MA 38688 A MA38688 A MA 38688A MA 38688 B1 MA38688 B1 MA 38688B1
Authority
MA
Morocco
Prior art keywords
oral administration
vitamin
pharmaceutically acceptable
acceptable salt
ibandronic acid
Prior art date
Application number
MA38688A
Other languages
English (en)
Other versions
MA38688A1 (fr
Inventor
Serra João Pedro Silva
Isabel Maria Soares
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50943510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38688(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of MA38688A1 publication Critical patent/MA38688A1/fr
Publication of MA38688B1 publication Critical patent/MA38688B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition pharmaceutique solide améliorée pour l'administration orale comprenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci, de la vitamine d et des triglycérides à chaîne moyenne ou des huiles totalement ou partiellement hydrogénées qui confère les propriétés physico-chimiques souhaitables à une formulation solide pour l'administration orale adaptée au traitement de maladies osseuses et de troubles du métabolisme du calcium.
MA38688A 2013-05-31 2014-05-30 Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d MA38688B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT106978A PT106978A (pt) 2013-05-31 2013-05-31 Composição sólida oral contendo ácido ibandrónico e vitamina d
PCT/PT2014/000036 WO2014193255A1 (fr) 2013-05-31 2014-05-30 Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d

Publications (2)

Publication Number Publication Date
MA38688A1 MA38688A1 (fr) 2017-07-31
MA38688B1 true MA38688B1 (fr) 2018-08-31

Family

ID=50943510

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38688A MA38688B1 (fr) 2013-05-31 2014-05-30 Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d

Country Status (16)

Country Link
US (1) US20160106766A1 (fr)
EP (1) EP3003383B1 (fr)
BR (1) BR112015029897A2 (fr)
CL (1) CL2015003468A1 (fr)
DK (1) DK3003383T3 (fr)
ES (1) ES2705074T3 (fr)
HU (1) HUE040666T2 (fr)
LT (1) LT3003383T (fr)
MA (1) MA38688B1 (fr)
MX (1) MX364680B (fr)
PL (1) PL3003383T3 (fr)
PT (2) PT106978A (fr)
RS (1) RS58133B1 (fr)
SI (1) SI3003383T1 (fr)
TR (1) TR201821157T4 (fr)
WO (1) WO2014193255A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1993559T (pt) 2006-02-03 2016-09-26 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
JP5444212B2 (ja) 2007-04-25 2014-03-19 シトクロマ インコーポレイテッド ビタミンｄ不足および欠乏症の治療方法
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
EP2552484B1 (fr) 2010-03-29 2020-01-08 Opko Ireland Global Holdings, Ltd. Procédés et compositions pour réduction de taux d'hormone parathyroïde
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
AU2003226148A1 (en) 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
EP2124963A4 (fr) * 2006-12-20 2010-03-17 Mylan Pharmaceuticals Ulc Composition contenant un acide bisphosphonique combiné à de la vitamine d
EP1972341A1 (fr) 2007-03-23 2008-09-24 Novartis AG Compositions pharmaceutiques contenant un bisphosphonate et de la vitamine D
WO2010075537A1 (fr) * 2008-12-23 2010-07-01 Teva Pharmaceutical Industries Ltd. Formule comprenant de la vitamine d ou ses dérivés
EP2416756A2 (fr) * 2009-04-10 2012-02-15 Mahmut Bilgic Compositions pharmaceutiques stables à forte biodisponibilité
IT1396937B1 (it) * 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
GB2502032B (en) * 2011-03-02 2015-03-04 D3 Pharma Ltd Stable Vitamin D3 Composition

Also Published As

Publication number Publication date
PL3003383T3 (pl) 2019-04-30
RS58133B1 (sr) 2019-02-28
MX2015016497A (es) 2016-09-08
DK3003383T3 (en) 2019-01-28
LT3003383T (lt) 2019-03-12
MA38688A1 (fr) 2017-07-31
PT3003383T (pt) 2019-01-16
SI3003383T1 (sl) 2019-03-29
TR201821157T4 (tr) 2019-02-21
BR112015029897A2 (pt) 2017-07-25
CL2015003468A1 (es) 2016-07-22
WO2014193255A1 (fr) 2014-12-04
MX364680B (es) 2019-05-03
US20160106766A1 (en) 2016-04-21
ES2705074T3 (es) 2019-03-21
EP3003383A1 (fr) 2016-04-13
EP3003383B1 (fr) 2018-10-03
PT106978A (pt) 2014-12-02
HUE040666T2 (hu) 2019-08-28

Similar Documents

Publication Publication Date Title
MA38688A1 (fr) Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d
MA43116B1 (fr) Ditosylate de valbénazine et polymorphes associés
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA54231B1 (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA37888A1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA35728B1 (fr) Dérivés de 6,7-dihydro-5h-benzo[7]annulène, leur procédé de préparation, préparations pharmaceutiques les contenant et leur utilisation pour la fabrication de produits pharmaceutiques
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA34333B1 (fr) Dérivés de 6,7-dihydro-5h-benzo[7]annulène, leur procédé de préparation, préparations pharmaceutiques les contenant et leur utilisation pour la fabrication de produits pharmaceutiques
MA35674B1 (fr) Derives de chromone, leur procede de preparation et leurs applications therapeutiques
MA38425B1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA38215A1 (fr) Composition pharmaceutique ophtalmologique topique contenant regorafenib
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA43793B1 (fr) Procédé de préparation de formulations solides de mésalazine
MA20150424A1 (fr) Compositions liquides orales pédiatriques contenant du nepadutant
MA56854B1 (fr) Inhibiteurs de kars dépendant d'akr1c3 tricycliques
FR3042191B1 (fr) Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives
MA53135B1 (fr) Composés de c-mannoside utiles pour le traitement d'infections des voies urinaires